Alcon moves and grows Swiss operations
This article was originally published in Clinica
Executive Summary
Alcon, the ophthalmic company owned by the Swiss conglomerate Nestle, is to double the size of its global administration operations in Switzerland and move them from their current location of Hunenberg to Fribourg. The relocation is expected to take over two years to complete, following which all administrative activities will be carried out at Fribourg. The company said it will remain resident in Hunenberg and continue to manage local sales and marketing activities from there.
You may also be interested in...
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.